Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Provexis

AIM:PXS
Snowflake Description

Adequate balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PXS
AIM
£9M
Market Cap
  1. Home
  2. GB
  3. Household
Company description

Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. The last earnings update was 91 days ago. More info.


Add to Portfolio Compare Print
  • Provexis has significant price volatility in the past 3 months.
PXS Share Price and Events
7 Day Returns
0%
AIM:PXS
11.9%
GB Personal Products
10%
GB Market
1 Year Returns
63.6%
AIM:PXS
-34.7%
GB Personal Products
-23%
GB Market
PXS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Provexis (PXS) 0% -10% -31.3% 63.6% -7.2% -10%
GB Personal Products 11.9% -24.8% -25.7% -34.7% -58.8% -31.7%
GB Market 10% -17.6% -27.3% -23% -24.2% -21.8%
1 Year Return vs Industry and Market
  • PXS outperformed the Personal Products industry which returned -34.7% over the past year.
  • PXS outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -23% over the past year.
Price Volatility
PXS
Industry
5yr Volatility vs Market

Value

 Is Provexis undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Provexis. This is due to cash flow or dividend data being unavailable. The share price is £0.0045.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Provexis's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Provexis's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:PXS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in GBP £0.00
AIM:PXS Share Price ** AIM (2020-03-31) in GBP £0
United Kingdom of Great Britain and Northern Ireland Personal Products Industry PE Ratio Median Figure of 5 Publicly-Listed Personal Products Companies 14.27x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 747 Publicly-Listed Companies 12.45x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Provexis.

AIM:PXS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:PXS Share Price ÷ EPS (both in GBP)

= 0 ÷ 0.00

-19.82x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Provexis is loss making, we can't compare its value to the GB Personal Products industry average.
  • Provexis is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Provexis's expected growth come at a high price?
Raw Data
AIM:PXS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -19.82x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Personal Products Industry PEG Ratio Median Figure of 14 Publicly-Listed Personal Products Companies 1.41x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 526 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Provexis, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Provexis's assets?
Raw Data
AIM:PXS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in GBP £0.00
AIM:PXS Share Price * AIM (2020-03-31) in GBP £0
United Kingdom of Great Britain and Northern Ireland Personal Products Industry PB Ratio Median Figure of 8 Publicly-Listed Personal Products Companies 0.94x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,322 Publicly-Listed Companies 1.08x
AIM:PXS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:PXS Share Price ÷ Book Value per Share (both in GBP)

= 0 ÷ 0.00

12.68x

* Primary Listing of Provexis.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Provexis is overvalued based on assets compared to the GB Personal Products industry average.
X
Value checks
We assess Provexis's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Personal Products industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Personal Products industry average (and greater than 0)? (1 check)
  5. Provexis has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Provexis expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Provexis has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
9.6%
Expected Personal Products industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Provexis expected to grow at an attractive rate?
  • Unable to compare Provexis's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Provexis's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
  • Unable to compare Provexis's revenue growth to the United Kingdom of Great Britain and Northern Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
AIM:PXS Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Personal Products Industry Earnings Growth Rate Market Cap Weighted Average 9.6%
United Kingdom of Great Britain and Northern Ireland Personal Products Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 2.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:PXS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:PXS Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
AIM:PXS Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-09-30 0 0 0
2019-06-30 0 0 0
2019-03-31 0 0 -1
2018-12-31 0 0 -1
2018-09-30 0 0 0
2018-06-30 0 0 0
2018-03-31 0 0 0
2017-12-31 0 0 0
2017-09-30 0 0 0
2017-06-30 0 0 0
2017-03-31 0 0 0
2016-12-31 0 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Provexis is high growth as no earnings estimate data is available.
  • Unable to determine if Provexis is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:PXS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Provexis Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:PXS Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
AIM:PXS Past Financials Data
Date (Data in GBP Millions) EPS *
2019-09-30 0.00
2019-06-30 0.00
2019-03-31 0.00
2018-12-31 0.00
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 0.00
2017-03-31 0.00
2016-12-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Provexis will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Provexis's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Provexis's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Household companies here
  3. Provexis's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Provexis's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Provexis has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Provexis performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Provexis's growth in the last year to its industry (Personal Products).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Provexis does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Provexis's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Provexis's 1-year growth to the Europe Personal Products industry average as it is not currently profitable.
Earnings and Revenue History
Provexis's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Provexis Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:PXS Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 0.35 -0.45 0.55 0.23
2019-06-30 0.34 -0.48 0.57 0.22
2019-03-31 0.32 -0.51 0.59 0.21
2018-12-31 0.31 -0.50 0.58 0.21
2018-09-30 0.31 -0.49 0.57 0.20
2018-06-30 0.27 -0.47 0.54 0.19
2018-03-31 0.24 -0.45 0.51 0.17
2017-12-31 0.23 -0.44 0.50 0.18
2017-09-30 0.23 -0.43 0.48 0.19
2017-06-30 0.23 -0.41 0.47 0.18
2017-03-31 0.23 -0.38 0.46 0.17
2016-12-31 0.20 -0.35 0.42 0.16
2016-09-30 0.17 -0.32 0.39 0.15
2016-06-30 0.13 -0.37 0.37 0.17
2016-03-31 0.09 -0.41 0.35 0.19
2015-12-31 0.08 -0.44 0.36 0.21
2015-09-30 0.07 -0.46 0.36 0.23
2015-06-30 0.05 -0.45 0.36 0.20
2015-03-31 0.04 -0.44 0.36 0.18
2014-12-31 0.03 -0.51 0.46 0.14
2014-09-30 0.01 -0.58 0.57 0.09
2014-06-30 0.01 -0.76 0.72 0.12
2014-03-31 0.00 -0.95 0.88 0.14
2013-12-31 0.01 -2.46 1.05 0.19
2013-09-30 0.03 -3.97 1.23 0.24
2013-06-30 0.03 -4.04 1.27 0.28

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Provexis has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Provexis has efficiently used its assets last year compared to the GB Personal Products industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Provexis improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Provexis's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Personal Products industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Provexis has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Provexis's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Provexis's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Provexis is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Provexis has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Provexis's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Provexis has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Provexis Company Filings, last reported 6 months ago.

AIM:PXS Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 0.21 0.00 0.17
2019-06-30 0.21 0.00 0.17
2019-03-31 0.34 0.00 0.33
2018-12-31 0.34 0.00 0.33
2018-09-30 0.18 0.00 0.56
2018-06-30 0.18 0.00 0.56
2018-03-31 0.33 0.00 0.32
2017-12-31 0.33 0.00 0.32
2017-09-30 0.54 0.00 0.48
2017-06-30 0.54 0.00 0.48
2017-03-31 0.02 0.00 0.01
2016-12-31 0.02 0.00 0.01
2016-09-30 0.27 0.00 0.24
2016-06-30 0.27 0.00 0.24
2016-03-31 0.14 0.00 0.19
2015-12-31 0.14 0.00 0.19
2015-09-30 0.33 0.00 0.35
2015-06-30 0.33 0.00 0.35
2015-03-31 0.25 0.00 0.29
2014-12-31 0.25 0.00 0.29
2014-09-30 0.40 0.00 0.37
2014-06-30 0.40 0.00 0.37
2014-03-31 0.54 0.00 0.51
2013-12-31 0.54 0.00 0.51
2013-09-30 0.64 0.00 0.56
2013-06-30 0.64 0.00 0.56
  • Provexis has no debt.
  • Provexis has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Provexis has less than a year of cash runway based on current free cash flow.
  • Provexis has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.6% each year.
X
Financial health checks
We assess Provexis's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Provexis has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Provexis's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Provexis dividends.
If you bought £2,000 of Provexis shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Provexis's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Provexis's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:PXS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Personal Products Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 2.5%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 629 Stocks 6%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.4%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2.7%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 7.5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:PXS Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Provexis has not reported any payouts.
  • Unable to verify if Provexis's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Provexis's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Provexis has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Provexis's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Provexis afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Provexis has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Provexis's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ian Ford
COMPENSATION £135,138
AGE 53
TENURE AS CEO 0.4 years
CEO Bio

Mr. Ian Ford, BA (Hons) ACA has been Chief Financial Officer at Provexis plc since April 12, 2019, serves as Chief Executive Officer since September 2019 and its Company Secretary since July 19, 2007 and served as its and Chief Operating Officer until September 2019. Mr. Ford served as Finance Director of Provexis plc. until April 12, 2019. Mr. Ford serves as senior finance positions with Rubicon Group plc and SITEL Europe plc, playing key roles in the rapid growth of these groups, including extensive merger and acquisition activity. He managed the turnaround and merger of the British Executive Service Overseas charity. He served as an Executive Director of Science in Sport plc from June 19, 2013 to June 28, 2013. He has been an Executive Director of Provexis plc since July 19, 2007. Mr. Ford is qualified as a chartered accountant in 1991 and spent his early career with PricewaterhouseCoopers.

CEO Compensation
  • Ian's compensation has increased whilst company is loss making.
  • Ian's remuneration is lower than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team

Ian Ford

TITLE
CEO, CFO
COMPENSATION
£135K
AGE
53
TENURE
0.4 yrs

Niamh O’Kennedy

TITLE
Chief Scientific Officer
AGE
45
TENURE
0.8 yrs

Asim Duttaroy

TITLE
Consultant & Member of Scientific Advisory Board
Board of Directors Tenure

Average tenure and age of the Provexis board of directors in years:

5.3
Average Tenure
49
Average Age
  • The tenure for the Provexis board of directors is about average.
Board of Directors

Charles Buck

TITLE
Non-Executive Chairman
COMPENSATION
£78K
AGE
72
TENURE
6.3 yrs

Ian Ford

TITLE
CEO, CFO
COMPENSATION
£135K
AGE
53
TENURE
12.7 yrs

Niamh O’Kennedy

TITLE
Chief Scientific Officer
AGE
45
TENURE
0.8 yrs

Asim Duttaroy

TITLE
Consultant & Member of Scientific Advisory Board
TENURE
5.3 yrs

Frédéric Boned

TITLE
Non-Executive Director
AGE
41
TENURE
1.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
X
Management checks
We assess Provexis's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Provexis has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Can We See Significant Insider Ownership On The Provexis plc (LON:PXS) Share Register?

Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. … Check out our latest analysis for Provexis AIM:PXS Ownership Summary, July 17th 2019 What Does The Institutional Ownership Tell Us About Provexis? … Insider Ownership Of Provexis The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

Are Provexis plc's (LON:PXS) Interest Costs Too High?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is financial flexibility worth the lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Does Provexis plc's (LON:PXS) -12% Earnings Drop Reflect A Longer Term Trend?

After reading Provexis plc's (LON:PXS) most recent earnings announcement (30 September 2018), I found it useful to look back at how the company has performed in the past and compare this against the latest numbers. … As a long term investor, I pay close attention to earnings trend, rather than the figures published at one point in time. … PXS is loss-making, with the most recent trailing twelve-month earnings of -UK£487.9k (from 30 September 2018), which compared to last year has become.

Simply Wall St -

How Financially Strong Is Provexis plc (LON:PXS)?

However, it also faces higher cost of capital given interest cost is generally lower than equity. … Is PXS growing fast enough to value financial flexibility over lower cost of capital. … Debt capital generally has lower cost of capital compared to equity funding

Simply Wall St -

Is Provexis plc's (LON:PXS) Balance Sheet Strong Enough To Weather A Storm?

Provexis plc (LON:PXS), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is PXS will have to follow strict debt obligations which will reduce its financial flexibility. … Is PXS right in choosing financial flexibility over lower cost of capital

Simply Wall St -

Will You Be Burnt By Provexis plc's (LON:PXS) Cash Burn?

The single most important question to ask when you’re investing in a loss-making company is – will they need to raise cash again, and if so, when? … View our latest analysis for Provexis What is cash burn? … Now you know that even if the company was to continue to shrink its opex at this rate, it will not be able to sustain its operations given the current level of cash reserves.

Simply Wall St -

What Does Provexis plc's (LON:PXS) Ownership Structure Look Like?

Private Company Ownership Potential investors in PXS should also look at another important group of investors: private companies, with a stake of 0.11%, who are primarily invested because of strategic and capital gain interests. … However, an ownership of this size may be relatively insignificant, meaning that these shareholders may not have the potential to influence PXS's business strategy. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

Provexis plc's (LON:PXS) Earnings Dropped -35.39%, How Did It Fare Against The Industry?

In this article, I will take a look at Provexis plc's (AIM:PXS) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past few years, along with how the rest of PXS's industry performed. … I look at the ‘latest twelve-month’ data, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Each year, for the past five years Provexis has seen an annual decline in revenue of -46.45%, on average.

Simply Wall St -

Will You Be Burnt By Provexis plc's (LON:PXS) Cash Burn?

The single most important question to ask when you’re investing in a loss-making company is – will they need to raise cash again, and if so, when? … AIM:PXS Income Statement Jan 29th 18 When will Provexis need to raise more cash? … Even though this is analysis is fairly basic, and Provexis still can cut its overhead further, or raise debt capital instead of coming to equity markets, the outcome of this analysis still gives us an idea of the company’s timeline and when things will have to start changing, since its current operation is unsustainable.

Simply Wall St -

Interested In The Consumer Discretionary Industry? Take A Look At Provexis plc (LON:PXS)

However, a structural shift for the personal product industry, in particular, is the growth in consumer power. … AIM:PXS PE PEG Gauge Jan 12th 18 The personal product industry is trading at a PE ratio of 23x, higher than the rest of the UK stock market PE of 18x. … If your initial investment thesis is around the growth prospects of Provexis, there are other personal products companies that have delivered higher growth, and perhaps trading at a discount to the industry average.

Simply Wall St -

Company Info

Description

Provexis plc, together with its subsidiaries, develops, licenses, and markets functional foods, medical foods, and dietary supplements worldwide. Its products include Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke. The company’s syrup and powder versions of Fruitflow are used in foods, beverages, and dietary supplement formats. It also offers Fruitflow + Omega-3, a supplement in capsule form that supports healthy blood flow and normal heart function. Provexis plc has a collaboration agreement with By-Health Co., Ltd. The company offers its products through retail stores, as well as online. Provexis plc was founded in 1999 and is based in Reading, the United Kingdom.

Details
Name: Provexis plc
PXS
Exchange: AIM
Founded: 1999
£9,266,946
2,059,321,507
Website: http://www.provexis.org
Address: Provexis plc
2 Blagrave Street,
Reading,
Berkshire, RG1 1AZ,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM PXS Ordinary Shares London Stock Exchange AIM Market GB GBP 24. Jun 2005
DB NZCA Ordinary Shares Deutsche Boerse AG DE EUR 24. Jun 2005
Number of employees
Current staff
Staff numbers
4
Provexis employees.
Industry
Personal Products
Household
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/31 20:31
End of day share price update: 2020/03/31 00:00
Last estimates confirmation: 2018/09/27
Last earnings filing: 2019/12/31
Last earnings reported: 2019/09/30
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.